JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$761M |
| 2 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$735M |
| 3 |
Zimmer Biomet
ZBH
|
+$542M |
| 4 |
Amazon
AMZN
|
+$439M |
| 5 |
iShares Core MSCI EAFE ETF
IEFA
|
+$438M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.01B |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$1.11B |
| 3 |
AABA
Altaba Inc
AABA
|
+$699M |
| 4 |
TJX Companies
TJX
|
+$682M |
| 5 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 22.01% |
| 2 | Financials | 14.82% |
| 3 | Technology | 12.49% |
| 4 | Healthcare | 9.61% |
| 5 | Consumer Discretionary | 8.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
DISH
2676
CALL
DELISTED
DISH Network Corp.
DISH
| $4.3M | ﹤0.01% |
90,000
-305,000
| -77% | -$15.2M |
2017 Q1
3 quarters
|
|
2677
Credit Acceptance
CACC
$5.48B
| $4.29M | ﹤0.01% |
13,272
-1,387
| -9% | -$412K |
2013 Q2
18 quarters
|
|
|
ETFC
2678
CALL
DELISTED
E*Trade Financial Corporation
ETFC
| $4.29M | ﹤0.01% |
86,600
-28,400
| -25% | -$1.3M |
2017 Q3
1 quarter
|
|
2679
Cartesian Therapeutics
RNAC
$223M
| $4.28M | ﹤0.01% |
14,544
+2,373
| +19% | +$1.04M |
2016 Q2
6 quarters
|
|
2680
LXP Industrial Trust
LXP
$3.59B
| $4.28M | ﹤0.01% |
88,634
-6,005
| -6% | -$309K |
2015 Q4
8 quarters
|
|
2681
Protagonist Therapeutics
PTGX
$9.06B
| $4.26M | ﹤0.01% |
+204,759
| New | +$3.63M |
2017 Q4
0 quarters
|
|
2682
Alto Ingredients
ALTO
$292M
| $4.26M | ﹤0.01% |
935,524
-32,268
| -3% | -$153K |
2016 Q3
5 quarters
|
|
2683
Akebia Therapeutics
AKBA
$240M
| $4.26M | ﹤0.01% |
+286,257
| New | +$4.75M |
2017 Q4
0 quarters
|
|
|
VRTV
2684
DELISTED
VERITIV CORPORATION
VRTV
| $4.25M | ﹤0.01% |
147,130
-45,458
| -24% | -$1.32M |
2014 Q3
13 quarters
|
|
2685
iShares MBS ETF
MBB
$36.6B
| $4.25M | ﹤0.01% |
39,867
+1,923
| +5% | +$205K |
2013 Q2
18 quarters
|
|
2686
CONMED
CNMD
$1.39B
| $4.25M | ﹤0.01% |
83,297
+67,052
| +413% | +$3.49M |
2013 Q2
18 quarters
|
|
2687
Perion Network
PERI
$334M
| $4.25M | ﹤0.01% |
1,401,022
-1,739,960
| -55% | -$5.54M |
2013 Q4
16 quarters
|
|
|
DISCK
2688
CALL
DELISTED
Discovery, Inc. Series C Common Stock
DISCK
| $4.23M | ﹤0.01% |
200,000
+150,000
| +300% | +$2.76M |
2017 Q3
1 quarter
|
|
|
EVHC
2689
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $4.22M | ﹤0.01% |
122,175
-470,630
| -79% | -$16.5M |
2013 Q3
17 quarters
|
|
2690
First Bancorp
FBNC
$2.58B
| $4.22M | ﹤0.01% |
119,389
+68,689
| +135% | +$2.49M |
2013 Q2
18 quarters
|
|
2691
Exponent
EXPO
$3.2B
| $4.21M | ﹤0.01% |
118,342
+94,942
| +406% | +$3.49M |
2013 Q2
18 quarters
|
|
2692
AXIS Capital
AXS
$6.92B
| $4.21M | ﹤0.01% |
83,651
-348,928
| -81% | -$18.6M |
2013 Q2
18 quarters
|
|
2693
Autoliv
ALV
$8.19B
| $4.19M | ﹤0.01% |
45,808
+40,317
| +734% | +$3.65M |
2013 Q2
18 quarters
|
|
2694
Comfort Systems
FIX
$60.8B
| $4.19M | ﹤0.01% |
95,990
+31,486
| +49% | +$1.29M |
2013 Q2
18 quarters
|
|
|
DISCK
2695
DELISTED
Discovery, Inc. Series C Common Stock
DISCK
| $4.19M | ﹤0.01% |
197,845
-31,564
| -14% | -$581K |
2013 Q2
18 quarters
|
|
|
EEQ
2696
DELISTED
Enbridge Energy Management Llc
EEQ
| $4.18M | ﹤0.01% |
342,871
-124,477
| -27% | -$1.56M |
2014 Q4
12 quarters
|
|
2697
CALL
Skyworks Solutions
SWKS
$12.8B
| $4.18M | ﹤0.01% |
44,000
-60,000
| -58% | -$6.26M |
2017 Q1
3 quarters
|
|
2698
CALL
Medtronic
MDT
$110B
| $4.17M | ﹤0.01% |
51,700
+29,800
| +136% | +$2.39M |
2017 Q3
1 quarter
|
|
2699
Bunge Global
BG
$20.5B
| $4.17M | ﹤0.01% |
62,171
-1,151,286
| -95% | -$78.3M |
2013 Q2
18 quarters
|
|
|
FLXN
2700
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $4.16M | ﹤0.01% |
166,171
+1,771
| +1% | +$43.4K |
2015 Q4
8 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2017 Portfolio in Review
As of Q4 2017, JP Morgan Chase held 5,783 positions worth $475B, up 4.7% from $453B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q4 2017 filing shows 812 new, 2,513 increased, 1,655 reduced and 342 closed positions. Its largest new stake was Delphi Technologies PLC Ordinary Shares: 2,961,446 shares worth $155M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $4.01B.
By sector, the portfolio is most concentrated in Miscellaneous at 22% of assets, down from 24% a quarter earlier, followed by Financials and Technology.
- JP Morgan Chase's largest Q4 2017 buy was Delphi Technologies PLC Ordinary Shares: 2,961,446 shares worth $155M.
- JP Morgan Chase added most to Johnson & Johnson in Q4 2017, an estimated $761M increase.
- JP Morgan Chase's biggest Q4 2017 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $4.01B.
- JP Morgan Chase fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $275M.
- JP Morgan Chase's ten largest holdings make up 18% of its $475B portfolio in Q4 2017.
- JP Morgan Chase opened 812 new positions and closed 342 in Q4 2017.
- JP Morgan Chase's portfolio value rose 4.7% quarter-over-quarter to $475B.
Based on JP Morgan Chase's 13F filing for Q4 2017, filed 13 Feb 2018.